Mark Vincent
Director/Board Member chez APTOSE BIOSCIENCES INC.
Fortune : 719 $ au 31/03/2024
Profil
Mark D.
Vincent is the founder of Sarissa, Inc. (founded in 2000) where he holds the title of Chief Executive Officer & Director since 2011.
He is currently working as an Independent Director at Aptose Biosciences, Inc. since 2007 and as an Associate Professor at the University of Western Ontario since 2008.
Dr. Vincent has previously worked as a Director at DRI Capital, Inc. and as a Director-Investigational Oncology at YM BioSciences, Inc. He obtained his doctorate degree from the University of Cape Town in 1976.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0,00% | 05/02/2024 | 433 ( 0,00% ) | 719 $ | 31/03/2024 |
Postes actifs de Mark Vincent
Sociétés | Poste | Début |
---|---|---|
APTOSE BIOSCIENCES INC. | Director/Board Member | 19/09/2007 |
Sarissa, Inc. | Founder | 01/01/2000 |
University of Western Ontario | Corporate Officer/Principal | 01/01/2008 |
Anciens postes connus de Mark Vincent
Sociétés | Poste | Fin |
---|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Director/Board Member | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formation de Mark Vincent
University of Cape Town | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
APTOSE BIOSCIENCES INC. | Health Technology |
Entreprise privées | 3 |
---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sarissa, Inc. |